Curon Biopharmaceutical – Talk Bio

Actionable Insights Powered by AI

Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events

8 months ago talkbio0Tagged Adverse event, amgen, Antibodies, Bispecific, CAR-T, Carvykti, China, Curon Biopharmaceutical, Evaluation procedure, File (record), Legend Biotech, Merck, United States Food and Drug Administration

Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti

Merck Acquires Clinical-Stage CD3xCD19 Bispecific Antibody for $700M

9 months ago talkbio0Tagged Antibodies, Bispecific, CD3xCD19, clinical-stage, Curon Biopharmaceutical, Merck, pharmaceutical acquisition

Merck, CD3xCD19 bispecific antibody, Curon Biopharmaceutical, clinical-stage, pharmaceutical acquisition